Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC) : an open-label, platform-adaptive randomised controlled trial

Autor: Christopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, Najib M Rahman, Gail Hayward, Duncan B Richards, Jienchi Dorward, David M Lowe, Joseph F Standing, Judith Breuer, Saye Khoo, Stavros Petrou, Kerenza Hood, Jonathan S Nguyen-Van-Tam, Mahendra G Patel, Benjamin R Saville, Joe Marion, Emma Ogburn, Julie Allen, Heather Rutter, Nick Francis, Nicholas P B Thomas, Philip Evans, Melissa Dobson, Tracie-Ann Madden, Jane Holmes, Victoria Harris, May Ee Png, Mark Lown, Oliver van Hecke, Michelle A Detry, Christina T Saunders, Mark Fitzgerald, Nicholas S Berry, Lazaro Mwandigha, Ushma Galal, Sam Mort, Bhautesh D Jani, Nigel D Hart, Haroon Ahmed, Daniel Butler, Micheal McKenna, Jem Chalk, Layla Lavallee, Elizabeth Hadley, Lucy Cureton, Magdalena Benysek, Monique Andersson, Maria Coates, Sarah Barrett, Clare Bateman, Jennifer C Davies, Ivy Raymundo-Wood, Andrew Ustianowski, Andrew Carson-Stevens, Ly-Mee Yu, Paul Little, Akosua A Agyeman, Tanveer Ahmed, Damien Allcock, Adrian Beltran-Martinez, Oluseye E Benedict, Nigel Bird, Laura Brennan, Julianne Brown, Gerard Burns, Mike Butler, Zelda Cheng, Ruth Danson, Nigel de Kare-Silver, Devesh Dhasmana, Jon Dickson, Serge Engamba, Stacey Fisher, Robin Fox, Eve Frost, Richard Gaunt, Sarit Ghosh, Ishtiaq Gilkar, Anna Goodman, Steve Granier, Aleksandra Howell, Iqbal Hussain, Simon Hutchinson, Marie Imlach, Greg Irving, Nicholas Jacobsen, James Kennard, Umar Khan, Kyle Knox, Christopher Krasucki, Tom Law, Rem Lee, Nicola Lester, David Lewis, James Lunn, Claire I. Mackintosh, Mehul Mathukia, Patrick Moore, Seb Morton, Daniel Murphy, Rhiannon Nally, Chinonso Ndukauba, Olufunto Ogundapo, Henry Okeke, Amit Patel, Kavil Patel, Ruth Penfold, Satveer Poonian, Olajide Popoola, Alexander Pora, Vibhore Prasad, Rishabh Prasad, Omair Razzaq, Scot Richardson, Simon Royal, Afsana Safa, Satash Sehdev, Tamsin Sevenoaks, Divya Shah, Aadil Sheikh, Vanessa Short, Baljinder S Sidhu, Ivor Singh, Yusuf Soni, Chris Thalasselis, Pete Wilson, David Wingfield, Michael Wong, Maximillian N J Woodall, Nick Wooding, Sharon Woods, Joanna Yong, Francis Yongblah, Azhar Zafar

Publikováno v: PANORAMIC Trial Collaborative Group, Butler, C C, Hobbs, F D R, Gbinigie, O A, Rahman, N M, Hayward, G, Richards, D B, Dorward, J, Lowe, D M, Standing, J F, Breuer, J, Khoo, S, Petrou, S, Hood, K, Nguyen-Van-Tam, J S, Patel, M G, Saville, B R, Marion, J, Ogburn, E, Allen, J, Rutter, H, Francis, N, Thomas, N P B, Evans, P, Dobson, M, Madden, T-A, Holmes, J, Harris, V, Png, M E, Lown, M, van Hecke, O, Detry, M A, Saunders, C T, Fitzgerald, M, Berry, N S, Mwandigha, L, Galal, U, Mort, S, Jani, B D, Hart, N D, Ahmed, H, Butler, D, McKenna, M, Chalk, J, Lavallee, L, Hadley, E, Cureton, L, Benysek, M, Andersson, M, Coates, M & Barrett, S 2023, ' Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial ', The Lancet, vol. 401, no. 10373, pp. 281-293 . https://doi.org/10.1016/S0140-6736(22)02597-1

Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee6937dbf90341fd2ff687fe41c3d612
https://hdl.handle.net/10023/27412

A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first‐line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin

Autor: Jason F. Lester, Gareth Griffiths, John D. Chester, Tony Elliott, Robert Jones, Simon J. Crabb, Chao Huang, Robert Huddart, Tracie-Ann Madden, Satinder Jagdev, Angela C. Casbard, A. Birtle, L. Evans

Publikováno v: BJU International. 126:292-299

Objectives To assess the efficacy and tolerability of the dual EGFR/VEGFR inhibitor, vandetanib, in combination with carboplatin and gemcitabine in the first line treatment of patients with advanced urolthelial cancer (UC) who were unsuitable for cis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f4c9403cf0701cab25ece2b770a585e
https://doi.org/10.1111/bju.15096

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

Autor: Catherine Jane Bale, Rachel Butler, S Waters, Angela C. Casbard, Sarah Moon, Andrew Foxley, Ramachandran Venkitaraman, Catrin Cox, Johnathan Joffe, Tracie-Ann Madden, Fouad S Alchami, Margherita Carucci, Robert H. Jones, Chris Twelves, Pavel Bezecny, Sacha J Howell

Publikováno v: Jones, R, Casbard, A, Carucci, M, Cox, C, Butler, R, Alchami, F, Madden, T-A, Bale, C, Bezecny, P, Joffe, J, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, Foxley, A & Howell, S 2020, ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION) : a multicentre, randomised, controlled, phase 2 trial ', The Lancet Oncology, vol. 21, no. 3, pp. 345-357 . https://doi.org/10.1016/S1470-2045(19)30817-4

Background Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of, the serine/threonine kinase, Akt. Akt inhibitors are anticipated to have maximal efficacy in combination with chemotherapy, targeted, or anti-hormonal dr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be3e1775f72f2c39bba92c189237cd97
https://pubmed.ncbi.nlm.nih.gov/32359499

Obesity Self-Management Education: A Community-Based Project for an Underserved Population

Autor: Reina Eisner, Ruth Ann Madden, Heather Kane

Publikováno v: Clinical Scholars Review. 6:30-38

Obesity is a disease linked to several cardiovascular and endocrine dysfunctions as well as decreased life expectancy and quality of life. Obesity management is a prevalent and persistent concern in primary care. We implemented an educational interve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::631f8b7137966338eabebfb13e8af35f
https://doi.org/10.1891/1939-2095.6.1.30

ToTem: A phase Ib trial of temisirolimus with gemcitabine and cisplatin

Autor: Simon Pacey, Paul M. Loadman, Gareth Griffiths, Alison Young, Margaret A. Knowles, Tracie-Ann Madden, Alison Birtle, Mirela Hategan, John D. Chester, Robert Jones, Sanjeev Kumar, Richard Adams, Angela C. Casbard, Javier Garcia Corbacho, Andrew Protheroe

Background: gemcitabine (G) and cisplatin (C) is a standard-of-care, combination chemotherapy regimen for neoadjuvant treatment of muscle-invasive and palliative treatment of advanced bladder cancer (BC). More effective regimens are urgently needed,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f38fcb7ea53c7acc828f1f3cbdfe7283
https://www.repository.cam.ac.uk/handle/1810/286033